Pharmacotherapy: Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD)

Dates: July 30, 2025

Meets: W from 9:00 AM to 12 N

Location: Zoom Webinar

Zoom - No Charge: $0.00

There are still openings remaining at this time.

Online registration is not available at this time. Please contact our office for more information.

Support Person: MidSOUTH  Phone: 501-296-1920  Email: support@midsouth.ualr.edu


Enroll Yourself


The growing knowledge of alcohol's neurobiological effects on the brain has led to the development of effective FDA-approved pharmacotherapy options for use in the treatment of alcohol use disorder. Also, with the high prevalence of untreated opioid use disorder and continued increase in opioid-related overdoses nationwide has created a greater need to increase access and availability to the three medications approved by the FDA to treat opioid use disorder.

Instructor will discuss the high prevalence, morbidity, and mortality associated with alcohol and opioid use disorders and the current evidence, effectiveness, and pharmacological profiles of the current FDA-approved pharmacotherapies indicated. Participants will review prescribing guidelines and protocols for each of the FDA-approved pharmacotherapy options, general patient and medications considerations in treatment selection, and special considerations for high-risk and specific patient populations. Also, review recent research findings indicating specific improved outcomes associated with each pharmacotherapy option, and discuss practical strategies for patient engagement and increasing use of pharmacotherapies for alcohol and opioid use disorder in the clinical practice setting.

Objectives:
  • Discuss the current practice guidelines for screening, assessment, and treatment planning for alcohol and opioid use disorder.
  • Describe the current FDA-approved pharmacotherapies for the management of these two disorders
  • Review the current epidemiologic trends and death rates for these disorders.
  • Review the goals of medication treatment.
  • Summarize the clinical pharmacology, efficacy, and safety of prescribing for these disorders.
  • Recognize the unique patient- and medication-specific considerations when selecting pharmacological treatments.
  • Describe best practice recommendations for initiating and stabilizing medications.

Notes:

This event is subject to priority registration. If you have a code, you may register yourself now. If you do not have a registration code, you are welcome to add yourself to the waitlist. Any registration spots avilable after the priority registration period is over will be awarded on a first-come first-served basis for those on the waitlist.
Fee: $0.00
Hours:3.00

Zoom Webinar

JoAn Laes

JoAn Laes, MD, DFASAM, FACMT is an addiction medicine physician in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as experience in outpatient treatment of opioid and other substance use disorders. She is also a core medical toxicology faculty for the Minnesota Poison Center, Minneapolis, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

Share

Email Information to Friend Print